Treatment response biomarkers: working towards personalised radiotherapy for lung cancer

Due to major advances in the field of radiation oncology, patients with lung cancer (LC) can now receive technically individualised radiotherapy treatments.However, in the era of precision oncology, radiotherapy-based treatment selection needs to be improved as many patients do not benefit or are not offered optimum therapies.Cost-effective robust biomarkers can address this knowledge gap and lead to individuals being offered more bespoke treatments leading to improved outcome.This narrative review discusses some of the current achievements and challenges in the realisation of personalised radiotherapy delivery in patients with LC.